KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Equity Average: 2017-2025

Historic Equity Average for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $9.4 billion.

  • Moderna's Equity Average fell 20.77% to $9.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 billion, marking a year-over-year decrease of 20.77%. This contributed to the annual value of $12.4 billion for FY2024, which is 24.93% down from last year.
  • Per Moderna's latest filing, its Equity Average stood at $9.4 billion for Q3 2025, which was down 3.78% from $9.7 billion recorded in Q2 2025.
  • Over the past 5 years, Moderna's Equity Average peaked at $19.0 billion during Q1 2023, and registered a low of $3.2 billion during Q1 2021.
  • For the 3-year period, Moderna's Equity Average averaged around $13.1 billion, with its median value being $12.3 billion (2024).
  • Per our database at Business Quant, Moderna's Equity Average surged by 387.89% in 2022 and then slumped by 31.51% in 2024.
  • Quarterly analysis of 5 years shows Moderna's Equity Average stood at $12.1 billion in 2021, then surged by 52.93% to $18.6 billion in 2022, then declined by 26.42% to $13.7 billion in 2023, then dropped by 16.41% to $11.4 billion in 2024, then declined by 20.77% to $9.4 billion in 2025.
  • Its Equity Average stands at $9.4 billion for Q3 2025, versus $9.7 billion for Q2 2025 and $10.5 billion for Q1 2025.